Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Injection site pain comparison of semaglutide vs dulaglutide
2019-003844-57Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of semaglutide and dulaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Intensity of injection site pain. Started Nov 2019; status: completed.
02
Drugs
semaglutidedulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2019-003844-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003844-57.